Idiopathic Hypereosinophilic Syndrome
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
Drugs
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Imatinib mesilate
(
GLEEVEC,
GLIVEC,
IMATINIB TEVA,
IMATINIB TEVA B.V.
),
Mepolizumab
(
NUCALA
)
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Imatinib mesilate
(
GLEEVEC,
GLIVEC,
IMATINIB TEVA,
IMATINIB TEVA B.V.
),
Mepolizumab
(
NUCALA
),
Sotatercept,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
A rare hematologic disease characterized by eosinophilia without evidence of clonality persisting for at least six months, for which no underlying cause can be identified. The condition is associated with signs of organ damage and dysfunction. Clinical manifestations are highly variable, depending on the organ systems involved, and include rapidly developing, life-threatening cardiovascular or neurological complications.